Effect of GBCA Use on Detection and Diagnostic Performance of the Central Vein Sign: Evaluation Using a 3-T FLAIR* Sequence in Patients With Suspected Multiple Sclerosis

Key Points

This research aims to assess the effect of gadolinium-based contrast agents (GBCA) on the detection and diagnostic performance of the central vein sign (CVS) in multiple sclerosis.
Evaluation of the postcontrast FLAIR sequence for central vein sign in multiple sclerosis patients.
Comparison of diagnostic performance metrics before and after GBCA administration.
The postcontrast FLAIR sequence significantly improves the detection rates of the central vein sign.
Diagnostic performance metrics indicate a positive correlation with GBCA use.

Evaluates GBCA influence on diagnostic performance of central vein sign in multiple sclerosis, suggesting improved detection methods.

The postcontrast FLAIR* sequence should be considered for CVS evaluation in future investigational trials and clinical practice.

No takes yet. Share an insight, caveat, or question.

Daboul et al. (2022) studied this question.

View Full Paper

Ask AI

Bookmark

Share